Latest News and Press Releases

Tevogen advances CRO evaluation to drive $20M+ revenue growth, expand global clinical capabilities, and support a scalable, cash-flow-oriented model.

Tevogen regains compliance with Nasdaq minimum bid price requirement.

Tevogen.AI head Mittul Mehta to speak at FabCon 2026 on agentic AI and adaptive data pipelines, advancing enterprise-ready intelligent data systems.

Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,...

Tevogen advances TVGN 489 for Long COVID, expanding HLA coverage to 65% of U.S. population and integrating digital monitoring capabilities.

Tevogen names interim leaders to advance diversified growth strategy and evaluate subsidiaries targeting $50M+ in annual revenue.

Tevogen CEO outlines potential subsidiary acquisitions targeting $50M+ revenue and positive cash flow to support long-term growth.

Tevogen signs LOI to evaluate Apozeal acquisition, advancing U.S.-focused generics strategy with 10 FDA-approved ANDAs and pipeline assets.

WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors (the “Board”) has approved a reverse...